Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women
1. Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant reduction was noted for ...
Tag: ER-positive breast cancer
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
#VisualAbstract: Adjuvant ibandronate does not improve survival in postmenopausal patients with ER⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer
Click to read this study in JAMA.
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression
Click to read this study in The Lancet Oncology.
Tamoxifen decreases recurrence rates at 25 years in lymph node-negative estrogen-receptor-positive and Erb-B2 Receptor Tyrosine Kinase 2-negative breast cancer
1. Tamoxifen reduced the long-term risk of breast cancer metastasis or recurrence and improved survival, especially in large, low-grade progesterone ...
#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer
Click to read the study in The Lancet Oncology.
